Oaktree Acquisition Corp. III Life Sciences (OACCW) Revenue History
Annual and quarterly revenue from 2024 to present
OACCW Revenue Over Time (2024–2025)
OACCW Revenue Growth History
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
OACCW Revenue Analysis (2024–2025)
Current Revenue & Growth
As of July 8, 2026, Oaktree Acquisition Corp. III Life Sciences (OACCW) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
OACCW's historical revenue data shows various trends over time.
Peer Comparison
Compared to Financial Services sector peers — including RLAY (+39.0% YoY), RXRX (+11.0% YoY), and IPOD. Compare OACCW vs RLAY →
OACCW Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| OACCWCurrent | $0 | - | - | - | |
 RLAY | $15M | +39.0% | -28.6% | -1971.6% | |
 RXRX | $75M | +11.0% | +85.4% | -867.9% | |
 IPOD | $0 | - | - | - | |
 BX | $13.8B | - | - | 51.9% |
OACCW Historical Revenue Data (2024–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-1,195,687 | - |
| 2024 | $0 | - | $0 | - | $-703 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
OACCW — Frequently Asked Questions
Quick answers to the most common questions about buying OACCW stock.
Is OACCW's revenue growth accelerating or slowing?
OACCW TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is OACCW's revenue history from 2024 to 2026?
Oaktree Acquisition Corp. III Life Sciences (OACCW) revenue history spans 2024 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is OACCW's long-term revenue growth rate (CAGR)?
Oaktree Acquisition Corp. III Life Sciences's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for OACCW.
Why does OACCW's quarterly revenue fluctuate?
OACCW quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Oaktree Acquisition Corp. III Life Sciences's revenue data from 2024 to 2026 shows full historical quarterly detail on this page.
How is OACCW's revenue distributed by segment?
OACCW reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does OACCW's revenue compare to industry peers?
Oaktree Acquisition Corp. III Life Sciences (OACCW) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.